How Patents Flagged for Delisting Can Still Delay Generic Competition

This Viewpoint discusses the legal entanglements that can block generic drug competition on patents flagged for delisting.

Authors

Institutions

Publication Details

Journal
JAMA Health Forum
Published
2026-11-06
DOI
https://doi.org/10.1001/jamahealthforum.2026.3842
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

How Patents Flagged for Delisting Can Still Delay Generic Competition

William B. Feldman, Sarah M. E. Gabriele
2 links
JAMA Health Forum
Pharmaceutical Economics and Policy
article

How Patents Flagged for Delisting Can Still Delay Generic Competition

William B. Feldman, Sarah M. E. Gabriele
article en

Abstract

This Viewpoint discusses the legal entanglements that can block generic drug competition on patents flagged for delisting.

JAMA Health ForumVol. 7(11)
Brigham and Women's Hospital (US), Harvard University (US), University of California, Los Angeles (US)
Peace, justice, and strong institutions
Openalex Percentile: Top 12%
Pharmaceutical Economics and Policy
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
How Patents Flagged for Delisting Can Still Delay Generic Competition — William B. Feldman, Sarah M. E. Gabriele · JAMA Health Forum (2026) | TGRS Research Map | TGRS